Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Joshua F ZeidnerDaniel J LeeMark FrattiniGil D FineJudy CostasKathryn KolibabaStephen P AnthonyDavid BearssB Douglas SmithPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Alvocidib can be safely administered prior to 7+3 induction with encouraging clinical activity. These findings warrant further investigation of alvocidib combinations in newly diagnosed AML. This study was registered at clinicaltrials.gov identifier NCT03298984.